journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/30201741/how-do-the-accrual-pattern-and-follow-up-duration-affect-the-hazard-ratio-estimate-when-the-proportional-hazards-assumption-is-violated
#1
Miki Horiguchi, Michael J Hassett, Hajime Uno
No abstract text is available yet for this article.
September 10, 2018: Oncologist
https://www.readbyqxmd.com/read/30201740/results-from-a-monocentric-long-term-analysis-of-23-patients-with-ovarian-sertoli-leydig-cell-tumors
#2
Sebastien Gouy, Alexandra Arfi, Amandine Maulard, Patricia Pautier, Enrica Bentivegna, Alexandra Leary, Cyrus Chargari, Catherine Genestie, Philippe Morice
BACKGROUND: Sertoli-Leydig cell tumors (SLCTs) represent less than 0.5% of ovarian tumors. Because of the rarity of this tumor and its peak in frequency at around 25 years of age, this study aimed to describe SLCT management strategies. OBJECTIVE: The objective of this study was to determine the management (i.e., conservative surgery and adjuvant chemotherapy) of ovarian SLCTs. RESULTS: This retrospective analysis included 23 patients treated for ovarian SLCTs...
September 10, 2018: Oncologist
https://www.readbyqxmd.com/read/30190302/an-open-label-phase-ib-dose-escalation-study-of-trc105-anti-endoglin-antibody-with-axitinib-in-patients-with-metastatic-renal-cell-carcinoma
#3
Toni K Choueiri, M Dror Michaelson, Edwin M Posadas, Guru P Sonpavde, David F McDermott, Andrew B Nixon, Yingmiao Liu, Zhenhua Yuan, Ben K Seon, Meghara Walsh, Manoj A Jivani, Bonne J Adams, Charles P Theuer
BACKGROUND: TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). SUBJECTS, MATERIALS, AND METHODS: Heavily pretreated mRCC patients were treated with TRC105 weekly (8 mg/kg and then 10 mg/kg) in combination with axitinib (initially at 5 mg b.i.d. and then escalated per patient tolerance to a maximum of 10 mg b...
September 6, 2018: Oncologist
https://www.readbyqxmd.com/read/30190301/minimal-increase-in-survival-throughout-the-years-in-patients-with-soft-tissue-sarcoma-with-synchronous-metastases-results-of-a-population-based-study
#4
Melissa Vos, Vincent K Y Ho, Astrid W Oosten, Cornelis Verhoef, Stefan Sleijfer
BACKGROUND: Treatment options for patients with metastatic soft tissue sarcoma (STS) have increased in the last decade. We aimed to examine whether this is associated with improved overall survival (OS) in patients with STS with synchronous metastases. PATIENTS AND METHODS: Patients diagnosed with STS and synchronous metastases from 1989 to 2014 were queried from The Netherlands Cancer Registry. Trends in OS were assessed by the Kaplan-Meier method and log-rank test in time intervals of 5 years, for the whole study population and in subgroups for liposarcomas, leiomyosarcoma, and other STS subtypes...
September 6, 2018: Oncologist
https://www.readbyqxmd.com/read/30190300/-i-need-to-know-what-makes-somebody-tick-%C3%A2-challenges-and-strategies-of-implementing-shared-decision-making-in-individualized-oncology
#5
Joschka Haltaufderheide, Sebastian Wäscher, Bernhard Bertlich, Jochen Vollmann, Anke Reinacher-Schick, Jan Schildmann
BACKGROUND: Shared decision-making (SDM) has been advocated as an ethical framework for decision-making in cancer care. According to SDM, patients make decisions in light of their values and based on the available evidence. However, SDM is difficult to implement in cancer care. A lack of applicability in practice is often reported. This empirical-ethical study explores factors potentially relevant to current difficulties in translating the concept of SDM into clinical practice. METHODS: This study was conducted with nonparticipant observation of the decision-making process in patients with gastrointestinal cancers for whom the benefit of adjuvant chemotherapy was uncertain according to clinical guidelines...
September 6, 2018: Oncologist
https://www.readbyqxmd.com/read/30190299/regorafenib-for-patients-with-metastatic-colorectal-cancer-who-progressed-after-standard-therapy-results-of-the-large-single-arm-open-label-phase-iiib-consign-study
#6
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean-François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia-Carbonero, Yull E Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni
BACKGROUND: In the phase III CORRECT trial, regorafenib significantly improved survival in treatment-refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization. METHODS: This prospective, single-arm study enrolled patients in 25 countries at 186 sites. Patients with treatment-refractory mCRC and an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1 received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle...
September 6, 2018: Oncologist
https://www.readbyqxmd.com/read/30181315/concordance-study-between-ibm-watson-for-oncology-and-clinical-practice-for-patients-with-cancer-in-china
#7
Na Zhou, Chuan-Tao Zhang, Hong-Ying Lv, Chen-Xing Hao, Tian-Jun Li, Jing-Juan Zhu, Hua Zhu, Man Jiang, Ke-Wei Liu, He-Lei Hou, Dong Liu, Ai-Qin Li, Guo-Qing Zhang, Zi-Bin Tian, Xiao-Chun Zhang
BACKGROUND: IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence-based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U...
September 4, 2018: Oncologist
https://www.readbyqxmd.com/read/30181314/genomic-landscape-of-adult-and-pediatric-bcr-abl1-like-b-lymphoblastic-leukemia-using-parallel-dna-and-rna-sequencing
#8
Eric A Severson, Jo-Anne Vergilio, Laurie M Gay, Sugganth Daniel, Amanda C Hemmerich, Julia A Elvin, Nicholas Britt, Michelle Nahas, Michael B Cohen, Charlotte Brown, Pratheesh Sathyan, Andrew Rankin, Vincent Miller, Jeffrey S Ross, Shakti H Ramkissoon
BCR-ABL1-like B-Acute Lymphoblastic Leukemia (B-ALL) is a subset of B-ALL with a poor prognosis that is found in all age groups. Definitive identification of these patients is difficult in routine clinical practice as gene expression profiling, the gold standard test, is not widely available. Comprehensive genomic profiling performed on 450 patients with extensive fusion profiling revealed a wide range of genomic alterations which were consistent with a classification of BCR-ABL1-like B-ALL in 29% of cases...
September 4, 2018: Oncologist
https://www.readbyqxmd.com/read/30181313/expenditures-on-oncology-drugs-and-cancer-mortality-to-incidence-ratio-in-central-and-eastern-europe
#9
Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, Razvan Popescu, Robert Pirker, Tanja Čufer, Semir Bešlija, Alexandru Eniu, Vladimir Todorović, Katerina Kopečková, Galia Kurteva, Zorica Tomašević, Agim Sallaku, Snezhana Smichkoska, Žarko Bajić, Branimir Sikic
BACKGROUND: There is a steady decline in cancer mortality in Western Europe (WE), but this trend is not so obvious in Central and Eastern Europe (CEE). One of the largest discrepancies between WE and CEE is the level of investment in cancer care. The objective of our analysis was to examine the correlation between mortality-to-incidence (M/I) ratio and expenditures on oncology drugs in CEE and WE. MATERIALS AND METHODS: This cross-sectional analysis was done on publicly available data...
September 4, 2018: Oncologist
https://www.readbyqxmd.com/read/30181312/improved-detection-of-circulating-epithelial-cells-in-patients-with-intraductal-papillary-mucinous-neoplasms
#10
LETTER
Go J Yoshida
No abstract text is available yet for this article.
September 4, 2018: Oncologist
https://www.readbyqxmd.com/read/30171068/oral-ondansetron-offers-effective-antidiarrheal-activity-for-carcinoid-syndrome-refractory-to-somatostatin-analogs
#11
Barbara Kiesewetter, Heying Duan, Wolfgang Lamm, Alexander Haug, Philipp Riss, Andreas Selberherr, Christian Scheuba, Markus Raderer
OBJECTIVES: Somatostatin analogs (SSAs) are standard for symptomatic patients with neuroendocrine tumors (NETs). However, most patients experience tachyphylaxis, and limited options exist for this so-called "refractory carcinoid syndrome." Recently, 5-HT3 antagonist ondansetron has been associated with reduction of bowel movement in a small series. The aim of this analysis was to assess effectiveness of ondansetron for symptomatic treatment of carcinoid syndrome. DESIGN AND PATIENTS: We have analyzed patients given ondansetron as bridging therapy for refractory carcinoid syndrome...
August 31, 2018: Oncologist
https://www.readbyqxmd.com/read/30171067/prognostic-value-of-the-progesterone-receptor-by-subtype-in-patients-with-estrogen-receptor-positive-her-2-negative-breast-cancer
#12
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, Robert Paridaens, Anita Giobbie-Hurder, Meredith M Regan, Giuseppe Viale, Beat Thürlimann, Ignace Vergote, Evangelia Christodoulou, Ben Van Calster, Patrick Neven
BACKGROUND: In estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER-2) negative breast cancers, the progesterone receptor (PR) is an independent prognostic marker. Little is known about the prognostic value of PR by tumor grade. We assessed this in two independent datasets. PATIENTS AND METHODS: Women with primary operable, invasive ER+ HER-2 negative breast cancer diagnosed between 2000 and 2012, treated at University Hospitals Leuven, were included...
August 31, 2018: Oncologist
https://www.readbyqxmd.com/read/30171066/the-role-of-primary-care-physicians-in-childhood-cancer-survivorship-care-multiperspective-interviews
#13
Christina Signorelli, Claire E Wakefield, Joanna E Fardell, Tali Foreman, Karen A Johnston, Jon Emery, Elysia Thornton-Benko, Afaf Girgis, Hanne C Lie, Richard J Cohn
BACKGROUND: Primary care physicians (PCPs) are well placed to provide holistic care to survivors of childhood cancer and may relieve growing pressures on specialist-led follow-up. We evaluated PCPs' role and confidence in providing follow-up care to survivors of childhood cancer. SUBJECTS, MATERIALS, AND METHODS: In Stage 1, survivors and parents (of young survivors) from 11 Australian and New Zealand hospitals completed interviews about their PCPs' role in their follow-up...
August 31, 2018: Oncologist
https://www.readbyqxmd.com/read/30158288/erlotinib-as-neoadjuvant-therapy-in-stage-iiia-n2-egfr-mutation-positive-non-small-cell-lung-cancer-a-prospective-single-arm-phase-ii-study
#14
Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
LESSONS LEARNED: The findings of this prospective, single-arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA-N2 epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).Erlotinib shows promise as a neoadjuvant therapy option in this patient population.Next-generation sequencing may be useful for predicting outcomes with preoperative tyrosine kinase inhibitors (TKIs) in patients with NSCLC...
August 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30158287/assessment-of-netest-clinical-utility-in-a-u-s-registry-based-study
#15
Eric Liu, Scott Paulson, Anthony Gulati, Jon Freudman, William Grosh, Sheldon Kafer, Prasana C Wickremesinghe, Ronald R Salem, Lisa Bodei
BACKGROUND: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood-based multigene assay for management of neuroendocrine tumors (NETs) in a real-world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch-and-wait) were evaluated. MATERIALS AND METHODS: Patients with NETs ( n = 100) were followed for 6-12 months...
August 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30158286/antitumor-effect-of-nivolumab-on-subsequent-chemotherapy-for-platinum-resistant-ovarian-cancer
#16
Yoshihide Inayama, Junzo Hamanishi, Noriomi Matsumura, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Tsukasa Baba, Katsuyuki Horie, Ikuo Konishi, Masaki Mandai
Platinum-resistant recurrent ovarian cancer is generally refractory to chemotherapy. Programmed cell death-1 (PD-1) signaling is a new target for antitumor therapy. The anti-PD-1 antibody nivolumab had a 10% durable complete response rate in our phase II clinical trial. However, how nivolumab affects sensitivity to subsequent chemotherapy remains unclear. We encountered several cases of unexpected antitumor response among patients who underwent palliative chemotherapy in the follow-up study of our phase II nivolumab trial (UMIN000005714)...
August 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30158285/the-current-and-evolving-landscape-of-first-line-treatments-for-advanced-renal-cell-carcinoma
#17
Emiliano Calvo, Camillio Porta, Viktor Grünwald, Bernard Escudier
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC). The VEGFR tyrosine kinase inhibitors (TKIs) pazopanib and sunitinib are FDA-approved first-line treatment options for advanced RCC; however, other treatment options in this setting are available, including the recently approved combination of nivolumab (anti-PD-1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein-4 [CTLA-4]) for patients with intermediate or poor risk...
August 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30139841/patient-clinician-discordance-in-perceptions-of-treatment-risks-and-benefits-in-older-patients-with-acute-myeloid-leukemia
#18
Areej El-Jawahri, Margaret Nelson-Lowe, Harry VanDusen, Lara Traeger, Gregory A Abel, Joseph A Greer, Amir Fathi, David P Steensma, Thomas W LeBlanc, Zhigang Li, Daniel DeAngelo, Martha Wadleigh, Gabriela Hobbs, Julia Foster, Andrew Brunner, Philip Amrein, Richard M Stone, Jennifer S Temel
BACKGROUND: Older patients (≥60 years) with acute myeloid leukemia (AML) face difficult decisions regarding treatment with "intensive" chemotherapy that carries significant toxicity for a small chance of a cure versus "nonintensive" chemotherapy to control the disease, but with fewer side effects. However, studies of how these patients understand the risks and benefits of such treatments are lacking. METHODS: We conducted a longitudinal study of older patients newly diagnosed with AML assessing patients' ( n = 100) and oncologists' ( n = 11) perceptions of treatment-related mortality at enrollment and prognosis at 1 month...
August 23, 2018: Oncologist
https://www.readbyqxmd.com/read/30139840/a-phase-i-dose-escalation-study-of-linsitinib-osi-906-a-small-molecule-dual-insulin-like-growth-factor-1-receptor-insulin-receptor-kinase-inhibitor-in-combination-with-irinotecan-in-patients-with-advanced-cancer
#19
S Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, Wells A Messersmith, Arvind Dasari, Colin D Weekes, Christopher H Lieu, Madeline Kane, Aik Choon Tan, Todd M Pitts, Stephen Leong
LESSONS LEARNED: The maximum tolerated dose of the combination of linsitinib and irinotecan is linsitinib 450 mg daily on days 1-3 every 7 days and irinotecan 125 mg/m2 days 1 and 8 of a 21-day cycle.The adverse effects associated with the combination are not significantly increased beyond what is expected of each drug as a single agent.Multiple negative trials of insulin-like growth factor-1 receptor inhibitors performed in unselected patient populations led to the early discontinuation of linistinib development and this trial...
August 23, 2018: Oncologist
https://www.readbyqxmd.com/read/30139839/systemic-treatment-of-metastatic-recurrent-uterine-leiomyosarcoma-a-changing-paradigm
#20
Rebecca C Arend, Michael D Toboni, Allison M Montgomery, Robert A Burger, Alexander B Olawaiye, Bradley J Monk, Thomas J Herzog
The treatment of metastatic and recurrent uterine leoimyosarcoma (uLMS) has evolved rapidly in the past several years. Leoimyosarcoma is extremely aggressive and responds poorly to traditional chemotherapeutics. Recent regulatory approval of novel treatment options has significantly expanded the therapeutic armamentarium, and the addition of these therapies has challenged clinicians to select and optimally sequence these new compounds. Additionally, the potential role of immunotherapy is being assessed in current uLMS clinical trials...
August 23, 2018: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"